Dr Jack Parry
30 April 2026
keywords: opioids anesthesia pain consciousness myelin oligodendrocyte kappa opioid receptor white matter
There are two things opioids do that the Myelin Mind has been circling without naming directly. They suppress pain. And in sufficient doses, or in the hands of an anesthesiologist, they suppress consciousness. These are not the same thing, though they are related. And both, when you follow the biology past the pharmacology, arrive at the white matter.
Pain is a chiasm event. It is not a signal that travels from the periphery to a passive receptor. It is an encounter between incoming nociceptive signal and the accumulated myelinated condition that meets it, shaped by everything the nervous system has previously learned about threat, context, safety, and survival. Two people with identical peripheral tissue damage experience pain differently, and the difference lives in the white matter. The myelinated structure of prior experience determines what the arriving signal becomes.
Consciousness, on the Myelin Mind account, is that encounter operating at full depth: the complete chiasm, the full meeting of grey matter arriving and white matter receiving. To suppress consciousness is to close the chiasm.
The question is where.
The opioid system has three main receptor types. The mu receptor is the one most associated with analgesia, euphoria, and addiction. It is the target of morphine, heroin, oxycodone, and fentanyl. The delta receptor modulates mood and analgesia. The kappa receptor produces analgesia, sedation, and at higher doses a dissociative hallucinatory state that feels nothing like the mu experience: dysphoric, visionary, deeply strange.
What the white matter literature has established is that the kappa opioid receptor is expressed on oligodendrocyte precursor cells and regulates their differentiation directly. Activating the kappa receptor promotes OPC maturation into myelinating oligodendrocytes. Removing it prevents remyelination. The body’s own kappa ligand, dynorphin, is part of the endogenous signalling system through which the nervous system manages its own myelination process.
This is the same structural finding as nicotine and cannabinoids: the nervous system designed a receptor for its own internal purposes, one of those purposes being the regulation of myelination, and an exogenous molecule has found its way to that receptor. The kappa receptor sits at the intersection of pain modulation and OPC maturation. When you take an opioid, you are not only acting on pain circuits. You are speaking to the cells that build white matter, in the language those cells already use to manage their own development.
The MS literature makes this concrete in an unexpected way. In the standard mouse model of multiple sclerosis, kappa opioid receptor expression in the spinal cord is significantly downregulated from the onset of disease. The loss of opioid receptors in the demyelinated tissue partially explains the central neuropathic pain that MS patients experience: not because pain signals are louder, but because the kappa receptor system that ordinarily modulates both pain and OPC maturation has been depleted alongside the myelin it was helping to maintain. Pain and demyelination are not separate symptoms. They are two consequences of the same receptor loss.
Pregnancy offers the mirror of this finding. Pregnant women express higher levels of endogenous opioids. Pregnant MS patients experience remission and fewer relapses. Three months after delivery, as endogenous opioid levels fall, relapse rates rise sharply. The endogenous opioid system is not incidental to the myelination process. It is part of it.
Chronic opioid exposure does what chronic nicotine exposure and chronic cannabis exposure also do: it disrupts the developmental timing of the very process it was acting on. Long-term mu receptor activation produces measurable white matter microstructural changes in frontal and limbic pathways. The ibogaine article on this site establishes that ibogaine’s partial reversal of opioid-induced damage involves upregulation of the two primary myelination markers in the internal capsule. The opioid inscribed a false condition. The ibogaine began to rewrite it.
This is also the Myelin Mind account of opioid addiction. The mu receptor activation produces an artificially intense chiasm event: a signal arriving with such force, carried by a molecule that the receptor was not designed for, that the white matter begins to reorganise around it. The accumulated condition shifts toward the false signal. The self, inscribed in white matter over years of genuine encounter with the world, is gradually overwritten by a pharmaceutical encounter that the myelination process cannot distinguish from the real one. Addiction is not weakness. It is the white matter doing exactly what it was built to do, which is to reorganise around the most powerful and consistent signal it receives.
General anesthesia is a different order of intervention. The question it poses to the Myelin Mind is the hardest one the framework faces: if consciousness arises at the chiasm, what does it mean to close the chiasm entirely and reversibly?
A 2024 study published in CNS Neuroscience and Therapeutics provided the first direct evidence that myelin is not merely present during general anesthesia but actively regulates its depth. Using isoflurane, the researchers established demyelination models and found that mice with disrupted myelin required significantly different anesthetic concentrations to reach equivalent levels of unconsciousness. The white matter is modulating the threshold at which the chiasm closes. More myelin means a higher dose is needed to suppress consciousness. Less myelin means consciousness is more easily extinguished.
This finding inverts the standard anesthesiological assumption that consciousness is a grey matter phenomenon and the white matter is passive connective tissue. The accumulated condition is not an inert backdrop. It is part of what the anesthetic is acting on. When an anesthesiologist titrates a dose, they are, unknowingly, titrating against white matter.
The transient white matter microstructure changes that DTI studies record during general anesthesia, measurable changes in white matter volume and diffusion metrics that resolve within days of recovery, suggest that the chiasm is not simply switched off under anesthesia. It is temporarily reorganised. Something happens in the white matter during unconsciousness that reverses on waking but is physically measurable while it is occurring.
What that something is remains genuinely unknown. It may be related to the changes in fluid dynamics that the glymphatic system undergoes during sleep, which general anesthesia partially replicates. It may be a direct effect of anesthetic agents on oligodendrocyte membrane physiology. It may be something that the current literature does not yet have the tools to see.
The Myelin Mind can say this much: consciousness is the chiasm. Closing it requires acting on both ends. The grey matter can be silenced by suppressing axonal firing. But if the white matter is also changing during anesthesia, and the evidence now suggests it is, then the accumulated condition is not simply waiting for the grey matter to return. It is participating in its own suspension.
There is one more thing worth noting, which sits at the edge of what the biology can currently say.
Children who undergo general anesthesia during the critical window of frontal myelination, roughly from birth to five years of age, show measurable effects on white matter development that correlate with the number of exposures. The anesthetic agents, propofol and sevoflurane among them, have been shown to induce OPC apoptosis and to disrupt myelination in developing primate brains. The same window that schizophrenia and the montelukast literature identify as the moment of maximum vulnerability is also the window in which repeated surgical anesthesia carries the greatest white matter risk.
The clinical implications are still being worked through, and no current guidelines recommend avoiding necessary surgery in young children on the basis of this evidence. But the convergence is striking: every exogenous agent that reaches the myelination process during the developmental window leaves a trace in the white matter that outlasts its pharmacological presence.
The plateau, once disrupted, does not simply resume where it left off.
Further Reading
The study demonstrating that kappa opioid receptor activation promotes OPC differentiation and remyelination in the EAE model of MS, and that KOR expression is downregulated in demyelinated spinal cord:
Mei F et al. Identification of the kappa-opioid receptor as a therapeutic target for oligodendrocyte remyelination. Journal of Neuroscience, 2016 — https://www.jneurosci.org/content/36/30/7925
The Nature Communications paper confirming that KOR activation alleviates EAE and promotes oligodendrocyte-mediated remyelination through OPC differentiation rather than immune modulation:
Liu X et al. Kappa opioid receptor activation alleviates experimental autoimmune encephalomyelitis and promotes oligodendrocyte-mediated remyelination. Nature Communications, 2016 — https://www.nature.com/articles/ncomms11120
The direct demonstration that myelin actively modulates the depth of isoflurane anesthesia, with demyelinated mice showing significantly altered anesthesia profiles:
Myelin modulates the process of isoflurane anesthesia through the regulation of neural activity. CNS Neuroscience and Therapeutics, 2024 — https://pmc.ncbi.nlm.nih.gov/articles/PMC11322027/
The PLOS One DTI study documenting transient but measurable white matter microstructure changes during sevoflurane general anesthesia, with the authors noting that the relationship between these changes and loss of consciousness warrants investigation:
Tang CY et al. Transient changes in white matter microstructure during general anesthesia. PLOS One, 2021 — https://pmc.ncbi.nlm.nih.gov/articles/PMC7997710/
The British Journal of Anaesthesia review of general anesthesia effects on developing white matter, covering propofol and sevoflurane OPC toxicity and the vulnerability window in early childhood:
General anaesthesia, the developing brain, and cerebral white matter alterations: a narrative review. British Journal of Anaesthesia, 2023 — https://www.bjanaesthesia.org/article/S0007-0912(23)00504-4/fulltext
The companion article on this site covering ibogaine’s upregulation of myelination markers following opioid exposure, and the white matter account of addiction as inscription by a false signal:
Mille Plateaux — https://myelinmind.com/mille-plateaux/
Jack Parry is a philosopher, polyglot and biomedical animator at Swinburne University of Technology. He is the author of The Myelin Mind: The Genesis of Meaning